# Global inequities in organ transplantation, 2008–2023: trends, unmet need, and policy implications

**Authors:** Peng Hao, Qing He, Haifeng Li, Xiaohong Qiu, Zhonghua Klaus Chen

PMC · DOI: 10.1016/j.eclinm.2026.103788 · 2026-02-12

## TL;DR

Organ transplants are increasing globally, but access remains highly unequal, with most growth in wealthy countries and significant gaps in poorer regions.

## Contribution

This study provides the first comprehensive analysis of global organ transplant trends and inequities from 2008 to 2023.

## Key findings

- Global transplants increased by 76%, but per-million population rates remain extremely low in low-HDI countries.
- Kidney transplants dominate global activity, while lung transplants show the fastest growth.
- Japan and Mongolia show outlier trends, highlighting the role of policy and sociocultural factors.

## Abstract

Solid organ transplantation is the definitive treatment for end-stage organ failure, yet access is highly inequitable worldwide. Comparable long-term evidence across organs, regions, and development settings remains limited.

Data from the WHO Global Observatory on Donation and Transplantation (GODT) for six solid organs (2008–2023) were analyzed. Per-million population (PMP) rates and the estimated annual percentage change (EAPC) were calculated; disparities by Human Development Index (HDI), WHO regions, and Global Burden of Disease 2021 (GBD 2021) regions were quantified using the slope index of inequality (SII) and concentration index (CI); and transplant capacity gap was estimated by comparing observed volumes with PMP benchmarks from very-high-HDI countries.

Global transplants rose 76% (101,990–179,091); PMP increased 15.1 → 23.1 (EAPC 2.5%). Kidney transplantation accounted for 65% of all solid organ transplants in 2023, representing the largest share of global activity; lung transplantation showed the fastest relative growth. Two procedures declined globally—pancreas-only transplantation and small-bowel transplantation. Absolute volumes were highest in the USA, China, and India, but PMP ranged from >120 (Spain, USA) to <5 in most low-HDI countries. Growth accrued mainly in very-high-HDI settings, with minimal contribution from low-HDI regions. Japan showed persistently low rates despite very-high-HDI status, whereas Mongolia achieved the world's highest EAPC despite low HDI. Inequality widened by SII (55.9 → 73.9), while CI fell modestly (0.61 → 0.53). Benchmarking indicated the largest transplant capacity gap for kidney (>200,000 procedures), then liver (>80,000) and heart (>30,000); coverage remained <10% in most low-HDI countries.

Global activity increased substantially but gains concentrated in very-high-HDI countries, and inequities persist. Outlier trajectories highlight sociocultural and policy factors beyond economic development. Large benchmark-based gaps—especially for kidney, liver, and heart—remain across low- and middle-HDI settings. Strategic investment in policy, infrastructure, and integration of transplantation within universal health coverage is essential to advance equitable access.

The Integrated Fund4150102990-58803-0/Prof. Dr. Z.K. Chen; The Fund of Guangzhou Key Laboratory of Organ Transplantation2025A03J4036.

## Full-text entities

- **Genes:** GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}
- **Diseases:** brain death (MESH:D001926), intestinal failure (MESH:D000090124), hepatitis-related liver failure (MESH:D017093), chronic diseases (MESH:D002908), Disease (MESH:D004194), Pancreas (MESH:D010190), PC (MESH:D009402), COVID-19 (MESH:D000086382), end-stage organ failure (MESH:D007676), diabetes (MESH:D003920)
- **Chemicals:** glucose (MESH:D005947), PMP (-), teduglutide (MESH:C494910)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12925128/full.md

---
Source: https://tomesphere.com/paper/PMC12925128